Similar articles

• Cardiac Biomarkers for the Prediction and Detection of Adverse Cardiac Events After Noncardiac Surgery: A Narrative Review.

  De Hert SG, Lurati Buse GA. De Hert SG, et al. Anesth Analg. 2020 Jul;131(1):187-195. doi: 10.1213/ANE.0000000000004711. Anesth Analg. 2020. PMID: 32102011 Review.
• Pre-operative cardiac risk assessment in noncardiac surgery: are natriuretic peptides the magic bullet?

  Bolliger D, Seeberger MD, Filipovic M. Bolliger D, et al. J Am Coll Cardiol. 2009 Oct 20;54(17):1607-8. doi: 10.1016/j.jacc.2009.06.029. J Am Coll Cardiol. 2009. PMID: 19833259 No abstract available.
• Search for biomarkers to identify surgical patients at high cardiovascular and perioperative mortality risk.

  Planas A, Ramasco F. Planas A, et al. Rev Esp Anestesiol Reanim. 2017 Dec;64(10):547-549. doi: 10.1016/j.redar.2017.09.002. Epub 2017 Nov 2. Rev Esp Anestesiol Reanim. 2017. PMID: 29102403 English, Spanish. No abstract available.
• Approach to Noncardiac Surgery in a Cardiac Patient: Do We Need to Modify?

  Kanchi M. Kanchi M. J Cardiothorac Vasc Anesth. 2019 Dec;33(12):3531-3534. doi: 10.1053/j.jvca.2019.07.135. Epub 2019 Jul 25. J Cardiothorac Vasc Anesth. 2019. PMID: 31416677 No abstract available.
• N-terminal pro B type natriuretic peptide in high cardiovascular-risk patients for noncardiac surgery: What is the current prognostic evidence?

  Malhotra AK, Ramakrishna H. Malhotra AK, et al. Ann Card Anaesth. 2016 Apr-Jun;19(2):314-20. doi: 10.4103/0971-9784.179636. Ann Card Anaesth. 2016. PMID: 27052075 Free PMC article. Review.